Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FINLAY-FR-1
- Development stage
- Unknown
- Lead developer
- Finlay Vaccine Institute
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
FINLAY-FR-1, also known as Soberana 01, is a protein subunit vaccine candidate developed for the prevention of COVID-19. It consists of a recombinant dimeric receptor binding domain (d-RBD) from the SARS-CoV-2 spike protein, expressed in Chinese hamster ovary cells and formulated with aluminium hydroxide gel as an adjuvant. In some formulations, it also includes outer membrane vesicles from Neisseria meningitidis group B. The vaccine is designed to induce neutralizing antibodies against the RBD of SARS-CoV-2 and has demonstrated strong immunogenicity and safety in clinical trials. It was developed by the Finlay Vaccine Institute in Cuba primarily for use as a prophylactic vaccine against COVID-19[1][3][6].
- Brand names
- Soberana 01Soberana01Soberana-01
- Other names
- FINLAY-FR-1FINLAY-FR1FINLAY-FR 1Soberana 01Soberana01Soberana-01
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on FINLAY-FR-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FINLAY-FR-1.